Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity during the call. The company plans to acquire a factory in the next 2-3 years, which will involve a capital expenditure (capex). However, for a large international order of around INR 600 crores, the company confirmed no immediate capex or related fund raise is required due to advance payments from the client. The company relies on third-party manufacturing facilities and intends to move towards owning a manufacturing unit as part of future growth, but funding details for this are not specified. Overall, no explic

Any current/future capex/capital investment/strategic investment?

Vaishali Pharma plans to acquire a manufacturing factory within the next 2-3 years to support business growth and increase control over production. Currently, the company operates through third-party manufacturing with agreements typically lasting five years and renewable. No immediate capex is required for executing large international orders, as advance payments are involved. The planned factory acquisition will enable vertical growth, especially in the formulation business, aiming to enhance EBITDA margins. This strategic investment aligns with the company’s goal to grow revenue to INR 500

Future growth expectations in sales/revenue/volumes?

Vaishali Pharma aims to achieve INR 500 crores revenue within the next five years. The company plans to grow significantly by shifting focus from API business (with lower margins) to higher-margin formulation, veterinary, and surgical products. Nutraceutical segment (currently ~5% revenue) is expected to grow significantly in the coming years. They anticipate introduction of 15-20 new products, including more gummies, in the domestic market. Export business covers about 40-45% of revenue with plans to deepen presence vertically in the existing ~50 countries rather than horizontal expansion. Pa

Future growth expectations in earnings/operating earnings/profits/EPS?

Vaishali Pharma aims to achieve INR 500 crores revenue within the next 5 years. Target EBITDA margin improvement to 25% from current levels (~16% for 9 months FY24). Focus on growing high-margin formulation, veterinary, and surgical products to boost EBITDA margins. Strategic expansion in formulations expected to increase margin sustainability and overall profitability. Planning to acquire a manufacturing facility in 2-3 years to support capacity expansion. Introduction of new product lines, including Healthy Biotin and Multivitamin Gummies with 15-20 products in the pipeline, aiming at boosti

Current/ Expected Orderbook/ Pending Orders?

Current order book for formulations (including surgical and veterinary) stands at INR 12+ crores. An export order valued around INR 600 crores is pending due to advance payment and paperwork issues, with resolution underway. The company expects this large order to significantly impact financials in the near future. The pending large order's completion is anticipated soon, as per management's optimism and ongoing efforts. Regular export order inflows continue across 40+ countries with a focus on niche and high margin products. The company aims for sustained growth by expanding formulation busin

IN US

Sale is live|00:00:00left today

Vaishali Pharma LtdQ4 FY25Pharmaceuticals & Biotechnology

Vaishali Pharma Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹7.83Market Cap: ₹97 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

Yes

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Vaishali Pharma aims to achieve INR 500 crores revenue within the next five years.
→The company plans to grow significantly by shifting focus from API business (with lower margins) to higher-margin formulation, veterinary, and surgical products.
→Nutraceutical segment (currently ~5% revenue) is expected to grow significantly in the coming years.
→They anticipate introduction of 15-20 new products, including more gummies, in the domestic market.
→Export business covers about 40-45% of revenue with plans to deepen presence vertically in the existing ~50 countries rather than horizontal expansion.
→Participation in international exhibitions like CPHI worldwide and others enhances client reach and business development.
→The company intends to acquire a manufacturing facility within 2-3 years to support capacity and growth.
→Overall, they expect sustained growth driven by product innovation, geographic focus, and strategic marketing efforts.

Margin guidance

Category 1

→Vaishali Pharma aims to achieve INR 500 crores revenue within the next 5 years.
→Target EBITDA margin improvement to 25% from current levels (~16% for 9 months FY24).
→Focus on growing high-margin formulation, veterinary, and surgical products to boost EBITDA margins.
→Strategic expansion in formulations expected to increase margin sustainability and overall profitability.
→Planning to acquire a manufacturing facility in 2-3 years to support capacity expansion.
→Introduction of new product lines, including Healthy Biotin and Multivitamin Gummies with 15-20 products in the pipeline, aiming at boosting domestic market growth.
→Anticipated significant impact from a likely INR 600 crore international export order pending advance payments.
→EPS for 9 months FY24 stands at INR 5.10, reflecting sustained profitability.
→Overall optimism based on proactive operational reassessment, new opportunities, and focus on long-term growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity during the call.
→The company plans to acquire a factory in the next 2-3 years, which will involve a capital expenditure (capex).
→However, for a large international order of around INR 600 crores, the company confirmed no immediate capex or related fund raise is required due to advance payments from the client.
→The company relies on third-party manufacturing facilities and intends to move towards owning a manufacturing unit as part of future growth, but funding details for this are not specified.
→Overall, no explicit plans for raising funds through debt or equity were discussed in this call transcript.

Order book

Yes

→Current order book for formulations (including surgical and veterinary) stands at INR 12+ crores.
→An export order valued around INR 600 crores is pending due to advance payment and paperwork issues, with resolution underway.
→The company expects this large order to significantly impact financials in the near future.
→The pending large order's completion is anticipated soon, as per management's optimism and ongoing efforts.
→Regular export order inflows continue across 40+ countries with a focus on niche and high margin products.
→The company aims for sustained growth by expanding formulation business and acquiring a factory within 2-3 years to increase capacity.

Capex plans

Yes

→Vaishali Pharma plans to acquire a manufacturing factory within the next 2-3 years to support business growth and increase control over production.
→Currently, the company operates through third-party manufacturing with agreements typically lasting five years and renewable.
→No immediate capex is required for executing large international orders, as advance payments are involved.
→The planned factory acquisition will enable vertical growth, especially in the formulation business, aiming to enhance EBITDA margins.
→This strategic investment aligns with the company’s goal to grow revenue to INR 500 crores with a 25% EBITDA margin within five years.

How does Vaishali Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Vaishali Pharma Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Vaishali Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio